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Tissue culture of immortal cell strains from diseased
patients is an invaluable resource for medical re-
search but is largely limited to tumor cell lines or
transformed derivatives of native tissues. Here we
describe the generation of induced pluripotent
stem (iPS) cells from patients with a variety of genetic
diseases with either Mendelian or complex inheri-
tance; these diseases include adenosine deaminase
deficiency-related severe combined immunodefi-
ciency (ADA-SCID), Shwachman-Bodian-Diamond
syndrome (SBDS), Gaucher disease (GD) type III,
Duchenne (DMD) and Becker muscular dystrophy
(BMD), Parkinson disease (PD), Huntington disease
(HD), juvenile-onset, type 1 diabetes mellitus (JDM),
Down syndrome (DS)/trisomy 21, and the carrier
state of Lesch-Nyhan syndrome. Such disease-spe-
cific stem cells offer an unprecedented opportunity
to recapitulate both normal and pathologic human
tissue formation in vitro, thereby enabling disease
investigation and drug development.
INTRODUCTION
Cell culture has been the backbone of basic biomedical research
for many decades, and countless insights into both normal and
pathologic cellular processes have been gleaned by studying
human cells explanted in vitro. Most of the human cell lines in
wide use today carry genetic and epigenetic artifacts of accom-
modation to tissue culture and are derived either from malignanttissues or are genetically modified to drive immortal growth
(Grimm, 2004). Primary human cells have a limited life span in
culture, a constraint that thwarts inquiry into the regulation of tis-
sue formation, regeneration, and repair. Indeed, many human
cell types have never faithfully been adapted for growth
in vitro, and the lack of accessible models of normal and patho-
logic tissue formation has rendered many important questions in
human development and disease pathogenesis inaccessible.
Human embryonic stem cells isolated from excess embryos
from in vitro fertilization clinics represent an immortal propaga-
tion of pluripotent cells that theoretically can generate any cell
type within the human body (Lerou et al., 2008; Murry and Keller,
2008). Human embryonic stem cells allow investigators to ex-
plore early human development through in vitro differentiation,
which recapitulates aspects of normal gastrulation and tissue
formation. Embryos shown to carry genetic diseases by virtue
of preimplantation genetic diagnosis (PGD; genetic analysis of
single blastomeres obtained by embryo biopsy) can yield stem
cell lines that model single-gene disorders (Verlinsky et al.,
2005), but the vast majority of diseases that show more complex
genetic patterns of inheritance are not represented in this pool.
A tractable method for establishing immortal cultures of plu-
ripotent stem cells from diseased individuals would not only fa-
cilitate disease research but also lay a foundation for producing
autologous cell therapies that would avoid immune rejection
and enable correction of gene defects prior to tissue reconstitu-
tion. One strategy for producing autologous, patient-derived
pluripotent stem cells is somatic cell nuclear transfer (NT). In
a proof of principle experiment, NT-embryonic stem (ES) cells
generated from mice with genetic immunodeficiency were
used to combine gene and cell therapy to repair the genetic de-
fect (Rideout et al., 2002). To date, NT has not proven success-
ful in the human and, given the paucity of human oocytes, isCell 134, 877–886, September 5, 2008 ª2008 Elsevier Inc. 877
Table 1. iPS Cells Derived from Somatic Cells of Patients with Genetic Disease
Name Disease Molecular Defect Donor Cell Age Sex
ADA ADA-SCID GGG >AGG, exon 7 and Del(GAAGA)
exon 10, ADA gene
Fibroblast 3 M Male
GD Gaucher disease type III AAC > AGC, exon 9, G-insertion,
nucleotide 84 of cDNA, GBA gene
Fibroblast 20 Y Male
DMD Duchenne muscular dystrophy Deletion of exon 45–52, dystrophin gene Fibroblast 6 Y Male
BMD Becker muscular dystrophy Unidentified mutation in dystrophin Fibroblast 38 Y Male
DS1, DS2 Down syndrome Trisomy 21 Fibroblast 1 Y, 1 M Male
PD Parkinson disease Multifactorial Fibroblast 57 Y Male
JDM Juvenile diabetes mellitus Multifactorial Fibroblast 42 Y Female
SBDS Swachman-Bodian-Diamond
syndrome
IV2 + 2T > C and IV3  1G > A, SBDS
gene
Bone marrow mesenchymal
cells
4 M Male
HD Huntington disease 72 CAG repeats, huntingtin gene Fibroblast 20 Y Female
LNSc Lesch-Nyhan syndrome (carrier) Heterozygosity of HPRT1 Fibroblast 34 Y Femaledestined to have limited utility. In contrast, introducing a set of
transcription factors linked to pluripotency can directly repro-
gram human somatic cells to produce induced pluripotent
stem (iPS) cells, a method that has been achieved by several
groups worldwide (Lowry et al., 2008; Park et al., 2008b; Taka-
hashi et al., 2007; Yu et al., 2007). Given the robustness of the
approach, direct reprogramming promises to be a facile source
of patient-derived cell lines. Such lines would be immediately
valuable for medical research, but current methods for reprog-
ramming require infecting the somatic cells with multiple viral
vectors, thereby precluding consideration of their use in trans-
plantation medicine at this time.
Human cell culture is an essential complement to research with
animal models of disease. Murine models of human congenital
and acquired diseases are invaluable but provide a limited repre-
sentation of human pathophysiology. Murine models do not al-
ways faithfully mimic human diseases, especially for human con-
tiguous gene syndromes such as trisomy 21 (Down syndrome or
DS). A mouse model for the DS critical region on distal human
chromosome 21 fails to recapitulate the human cranial abnormal-
ities commonly associated with trisomy 21 (Olson et al., 2004).
Orthologous segments to human chromosome 21 are present
on mouse chromosomes 10 and 17, and distal human chromo-
some 21 corresponds to mouse chromosome 16 where trisomy
16 in the mouse is lethal (Nelson and Gibbs, 2004). Thus, a true
murine equivalent of human trisomy 21 does not exist. Murine
strains carrying the same genetic deficiencies as the human
bone marrow failure disease Fanconi anemia demonstrate DNA
repair defects consistent with the human condition (e.g., Chen
et al., 1996), yet none develop the spontaneous bone marrow
failure that is the hallmark of the human disease.
For cases where murine and human physiology differ, dis-
ease-specific pluripotent cells capable of differentiation into
the various tissues affected in each condition could undoubtedly
provide new insights into disease pathophysiology by permitting
analysis in a human system, under controlled conditions in vitro,
using a large number of genetically modifiable cells, and in
a manner specific to the genetic lesions in each whether known
or unknown. Here, we report the derivation of human iPS cell
lines from patients with a range of human genetic diseases.878 Cell 134, 877–886, September 5, 2008 ª2008 Elsevier Inc.RESULTS AND DISCUSSION
Dermal fibroblasts or bone marrow-derived mesenchymal cells
were obtained from patients with a prior diagnosis of a specific
disease and used to establish disease-specific lines of human
iPS cells (Table 1). This initial cohort of cell lines was derived
from patients with Mendelian or complex genetic disorders, in-
cluding Down syndrome (DS; trisomy 21); adenosine deami-
nase deficiency-related severe combined immunodeficiency
(ADA-SCID); Shwachman-Bodian-Diamond syndrome (SBDS);
Gaucher disease (GD) type III; Duchenne type (DMD) and
Becker type (BMD) muscular dystrophy; Huntington chorea
(Huntington disease; HD); Parkinson disease (PD); juvenile-on-
set, type 1 diabetes mellitus (JDM); and Lesch-Nyhan syn-
drome (LNSc; carrier state).
Patient-derived somatic cells were transduced with either four
(OCT4, SOX2, KLF4, and c-MYC) or three reprogramming fac-
tors (lacking c-MYC). Following 2 to 3 weeks of culture in hES
cell-supporting conditions, compact refractile ES-like colonies
emerged among a background of fibroblasts, as previously de-
scribed (Park et al., 2008a, 2008b). Although our previous report
used additional factors (hTERT and SV40 LT) to achieve reprog-
ramming of adult somatic cells, we have found the four-factor
cocktail to be sufficient as long as we employ a higher multiplicity
of retroviral infection. Additionally, we generated a single line
from a carrier of Lesch-Nyhan syndrome using five doxycy-
cline-inducible lentiviral vectors (OCT4, SOX2, KLF4, c-MYC,
and NANOG), a strategy that has been used to isolate murine
iPS cells (Brambrink et al., 2008; Stadtfeld et al., 2008) but
previously had not been attempted with human somatic cells.
Characterization of the iPS cell lines is presented below.
Mutation Analysis in iPS Cell Lines
The iPS cell lines were evaluated to confirm, where possible, the
disease-specific genotype of their parental somatic cells. Analy-
sis of the karyotype of iPS cell lines derived from two individuals
with Down syndrome showed the characteristic trisomy 21
anomaly (Figure 1A). Aneuploidies such as that occurring in DS
are unambiguously associated with advanced maternal age (re-
viewed in Antonarakis et al., 2004) and, as such, are occasionally
Figure 1. Genotypic Analysis of Disease-Specific iPS Cell Lines
(A) Two different, primary fibroblast specimens, DS1 and DS2 from male patients with Down syndrome (trisomy 21), were used to derive DS1-iPS4 and
DS2-iPS10. Each has a 47, XY + 21 karyotype over several passages (G-banding analysis).
(B) Fibroblast (ADA and GBA) or bone marrow mesenchymal cells (SBDS) were used to generate iPS cell lines. Mutated alleles identical to the original specimens
were verified by DNA sequencing. Adenosine deaminase deficiency line ADA-iPS2 is a compound heterozygote: GGG to GAA double transition in exon 7 of one
allele (G216R substitution); the second allele is an exon 10 frameshift deletion (-GAAGA) (Hirschhorn et al., 1993). Shwachman-Bodian-Diamond syndrome line
SBDS-iPS8 is also a compound heterozygote: point mutations at the IV2 + 2T > C intron 2 splice donor site and an IVS3  1G > A mutation of the SBDS gene
(Austin et al., 2005). GD-iPS3 (Gaucher disease type III): a 1226A > G point mutation (N370S substitution) and a guanine insertion at nucleotide 84 of the cDNA
(84GG) (Beutler et al., 1991).
(C) Fibroblasts from patients diagnosed with either Duchenne (DMD) or Becker type muscular dystrophy (BMD): DMD-iPS1 has a deletion over exons 45–52 (mul-
tiplex PCR for the dystrophin gene). We could not determine a deletion in BMD-iPS1 using two different multiplex PCR sets though these assays do not cover the
entire coding region. DMD2 is a patient control (exon 4 deletion). The control is genomic DNA from a healthy volunteer. Huntington disease (HD) is caused by
a trinucleotide repeat expansion within the huntingtin locus. DNA sequencing shows that HD-iPS1 has one normal (<35 repeats) and one expanded allele (72
repeats). HD2 is a positive control from a second Huntington patient with one normal and one expanded allele (54 repeats). The control is genomic DNA from
a healthy volunteer.Cell 134, 877–886, September 5, 2008 ª2008 Elsevier Inc. 879
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detected in the preimplantation embryo when in vitro fertilization
(IVF) is coupled with PGD. While it is possible that a discarded
IVF embryo found to have trisomy 21 could be donated to at-
tempt hES cell derivation, it is important to point out that many
gestating DS embryos do not survive the prenatal period.
Some studies place the frequency of spontaneous fetal demise
(miscarriage) in DS to be above 40% (Bittles et al., 2007).
Thus, the derivation of a human iPS cell line with trisomy 21
from an existing individual may be preferable, as such a line is
most likely to harbor the complex genetic and epigenetic modi-
fiers that favor full-term gestation and, by virtue of the often
lengthy medical history, will be a more informative resource for
correlative clinical research.
Creation of iPS cell lines from patients with single-gene disor-
ders allows experiments on disease phenotypes in vitro, and an
opportunity to repair gene defects ex vivo. The resulting cells, by
virtue of their immortal growth in culture, can be extensively
characterized to ensure that gene repair is precise and specific,
thereby reducing the safety concerns of random, viral-mediated
gene therapy. Repair of gene defects in pluripotent cells pro-
vides a common platform for combined gene repair and cell re-
placement therapy for a variety of genetic disorders, as long as
the pluripotent cells can be differentiated into relevant somatic
stem cell or tissue populations.
Three diseases in our cohort of iPS cells are inherited in a clas-
sical Mendelian manner as autosomal recessive congenital dis-
orders and are caused by point mutations in genes essential for
normal immunologic and hematopoietic function: adenosine de-
aminase deficiency, which causes severe combined immune
deficiency (ADA-SCID) due to the absence of T cells, B cells,
and NK cells; Shwachman-Bodian-Diamond syndrome, a con-
genital disorder characterized by exocrine pancreas insuffi-
ciency, skeletal abnormalities, and bone marrow failure; and
Gaucher disease type III, an autosomal recessive lysosomal
storage disease characterized by pancytopenia and progressive
neurological deterioration due to mutations in the acid beta-glu-
cosidase (GBA) gene. Sequence analysis of the ADA gene in the
disease-associated ADA-iPS2 cell line revealed a compound
heterozygote: a GGG to GAA transition mutation at exon 7, caus-
ing a G216R amino acid substitution (Figure 1B); the other allele
is known to have a frameshift deletion (-GAAGA) in exon 10
(Hirschhorn et al., 1993). The SBDS-iPS8 cell line harbors point
mutations at the IV2 + 2T > C intron 2 splice donor site
(Figure 1B) and IVS3  1G > A mutation (Austin et al., 2005). Mo-
lecular analysis of the GBA gene in the Gaucher disease line re-
vealed a 1226A > G point mutation, causing a N370S amino acid
substitution (Figure 1B); the second allele is known to have a fra-
meshifting insertion of a single guanine at cDNA nucleotide 84
(84GG) (Beutler et al., 1991). The Lesch-Nyhan syndrome carrier
line harbors heterozygous deficiency of the HPRT gene (Nuss-
baum et al., 1983).Two lines were derived from dermal fibroblasts cultured from
patients with muscular dystrophy. Multiplex PCR analysis with
primer sets amplifying several (but not all) intragenic intervals
of the dystrophin gene (Beggs et al., 1990; Chamberlain et al.,
1988) revealed the deletion of exons 45–52 in the iPS cells de-
rived from a patient with Duchenne muscular dystrophy (DMD;
Figure 1C). Despite analysis for gross genomic defects by multi-
plex PCR, a deletion was not detected in iPS cells derived from
a patient with Becker type muscular dystrophy (BMD; Figure 1C).
As BMD is a milder form of disease, and the dystrophin gene one
of the largest in the human genome, definition of the genetic le-
sion responsible for this condition is sometimes elusive (Prior
and Bridgeman, 2005).
Given that numerous groups have pioneered the directed dif-
ferentiation of neuronal subtypes, and that genetically defined
ES cells from animal models of amyotrophic lateral sclerosis
have revealed important insights into the pathophysiology of mo-
tor neuron deterioration (Di Giorgio et al., 2007), there is consid-
erable interest in generating iPS cell lines from patients afflicted
with neurodegenerative disease. We generated iPS cell lines
from a patient with Huntington chorea (Huntington disease;
HD) and verified the presence of expanded (CAG)n polyglut-
amine triplet repeat sequences (72) in the proximal portion of
the huntingtin gene (Figure 1C; Riess et al., 1993) in one allele
and 19 repeats in the other (where the normal range is 35 or
less; Chong et al., 1997).
Pluripotent cell lines will likewise be valuable for studying neu-
rodegenerative conditions with more complex genetic predispo-
sition, as well as metabolic diseases known to have familial pre-
dispositions but for which the genetic contribution remains
unexplained. We have generated lines from a patient diagnosed
with Parkinson disease (PD) and another from a patient with ju-
venile-onset (type I) diabetes mellitus (Table 1). Given that these
conditions lack a defined genetic basis, genotypic verification is
impossible at this time.
The Lesch-Nyhan syndrome is caused by mutations in hypo-
xanthine-guanine phosphoribosyltransferase (HPRT), an X-
linked enzyme in purine metabolism that when deficient leads
to abnormal accumulation of uric acid and a neurologic disorder
characterized by cognitive deficits and self-mutilating behavior.
Cells carrying either intact or deficient HPRT enzyme function
can be selectively cultured in media containing hypoxanthine-
Aminopterin-Thymidine (HAT) or 6-thioguanine (6-TG), respec-
tively. Strategies for inducing specific mutation or gene repair
by homologous recombination were first established for the
HPRT locus (Doetschman et al., 1987, 1988; Thomas and Ca-
pecchi, 1987). We have generated an iPS cell line from a female
carrier (LNSc-iPS2) that will be a valuable resource for studies of
homologous recombination in iPS cells and for analysis of X
chromosome reactivation during reprogramming and random
inactivation with differentiation.Figure 2. Disease-Specific iPS Cell Lines Exhibit Markers of Pluripotency
ADA-iPS2, GD-iPS1, DMD-iPS1, BMD-iPS1, DS1-iPS4, DS2-iPS10, PD-iPS1, JDM-iPS1, SBDS-iPS1, HD-iPS4, and LNSc-iPS2 were established from fibroblast
or mesenchymal cells (Table 1). Disease-specific iPS cell lines maintain a morphology similar to hES cells when grown in coculture with mouse embryonic feeder
fibroblasts (MEFs). Disease-specific iPS cells express alkaline phosphatase (AP). Also, as shown here via immunohistochemistry, disease-specific cells express
pluripotency markers including Tra-1–81, NANOG, OCT4, Tra-1-60, SSEA3, and SSEA4. 4,6-Diamidino-2-phenylindole (DAPI) staining is shown at right and
indicates the total cell content per image.Cell 134, 877–886, September 5, 2008 ª2008 Elsevier Inc. 881
Figure 3. Expression of Pluripotency-Associated Genes Is Elevated in Disease-Specific iPSCell Lines Relative to Their Somatic Cell Controls
In each panel, quantitative real-time PCR (RT-PCR) assay for OCT4, SOX2, NANOG, REX1, GDF3, and hTERT indicates increased expression in patient-specific
iPS cells relative to parent cell lines while expression of KLF4 and cMYC remains largely unchanged. PCR reactions were normalized against internal controls
(b-ACTIN) and plotted relative to expression levels in their individual parent fibroblast cell lines.
(A) the human iPS cell lines ADA-iPS2 and -iPS3 are derived from the adenosine deaminase deficiency-severe combined immunodeficiency fibroblast line ADA.
(B) GD-iPS1 and -iPS3 are derived from the Gaucher disease type III fibroblast line GD.
(C) DMD-iPS1 and -iPS2 are derived from the Duchenne muscular dystrophy fibroblast line DMD.
(D) BMD-iPS1 and -iPS4 are derived from the Becker muscular dystrophy line BMD.
(E) DS1-iPS4 is derived from the Down syndrome fibroblast line DS1.
(F) DS2-iPS1 and -iPS10 are derived from the Down syndrome fibroblast line DS2.
(G) PD-iPS1 and -iPS5 are derived from the Parkinson disease fibroblast line PD.
(H) JDM-iPS2 and -iPS4 are derived from the juvenile-onset, type 1 diabetes mellitus line JDM.
(I) SBDS-iPS1 and -iPS3 are derived from the Shwachman-Bodian-Diamond syndrome bone marrow mesenchymal fibroblast line SBDS.
(J) HD-iPS4 and -iPS11 are derived from the Huntington disease fibroblast line HD.
(K) LNSc-iPS1 and -iPS2 are derived from the Lesch-Nyhan syndrome carrier fibroblast line LNSc.
(L) Detroit 551 human fibroblasts are used as the standard here in order to demonstrate the previously described expression pattern in Detroit 551-derived iPS
cells (551-iPS8) relative to two bona fide hES cell lines: H1-OGN and BG01.Characterization of Disease-Specific iPS Cell Lines
All iPS cell colonies, which were selected based on their mor-
phologic resemblance to colonies of ES cells, demonstrated
compact colony morphology and markers of pluripotent cells,882 Cell 134, 877–886, September 5, 2008 ª2008 Elsevier Inc.including alkaline phosphatase (AP), Tra-1–81, Tra-1–60, OCT4,
NANOG, SSEA3, and SSEA4 (Figure 2). Quantitative RT-PCR in-
dicated the expression of pluripotency-related genes including
OCT4, SOX2, NANOG, REX1, GDF3, and hTERT regardless of
Figure 4. Pluripotency-Promoting Genes Are Chiefly Expressed from the Endogenous Loci in Disease-Specific iPS Cell Lines, While the
Virally Delivered Transgene Is Predominantly Silenced
The disease-specific iPS cell lines shown here are preceded by their parental fibroblast controls (from left to right at top): adenosine deaminase deficiency-as-
sociated severe combined immunodeficiency (ADA), Becker muscular dystrophy (BMD), Parkinson disease (PD), juvenile type 1 diabetes mellitus (JDM), Hun-
tington disease (HD), Detroit 551 control cells, Duchenne muscular dystrophy (DMD), Shwachman-Bodian-Diamond syndrome (SBDS), Down syndrome (DS),
Gaucher disease type III (GD), and Lesch-Nyhan syndrome carrier (LNSc). The semiquantitative expression (RT-PCR) of the four pluripotency-promoting genes
used in the reprogramming process, OCT4, SOX2, cMYC, KLF4, and NANOG is shown for each line using amplification conditions specific to the endogenous
(Endo) or virally delivered transgene (Trans) as well as the total expression for each (Total). b-ACTIN is shown at the bottom as a loading control for each lane.the genetic condition represented within the parental somatic
cells (Figure 3; control lines are shown in panel L). Retroviral
transgenes were largely silenced in the iPS cell lines, with ex-
pression of the relevant reprogramming factors assumed by en-
dogenous loci (Figure 4), as described (Park et al., 2008b). PCR-
based DNA fingerprint analysis using a highly variable number of
tandem repeats (VNTR) confirmed that the iPS cell lines were ge-
netically matched to their parental somatic lines, ruling out the
possibility of crosscontamination from existing cultures of hu-
man pluripotent cells (Figure S1 available online). Also, iPS cells
showed normal 46 XX or 46 XY karyotypes (Figure S2).
Human disease-associated iPS cell lines were characterized
by a standard set of assays to confirm pluripotency and multili-
neage differentiation. iPS cell lines (n = 7) were allowed to differ-
entiate in vitro into embryoid bodies as described (Park et al.,
2008b), and their potential to develop along specific lineages
was confirmed by PCR for markers of all three embryonic germ
layers (ectoderm, mesoderm, and endoderm; Figure 5A). Hema-
topoietic differentiation of disease-specific iPS cell lines (n = 2)
produced myeloid and erythroid colony types (Figure 5B). The ul-
timate standard of pluripotency for human cells is teratoma for-
mation in immunodeficient murine hosts (Lensch et al., 2007).
When injected intramuscularly into immunodeficient Rag2/
gC/ mice, disease-specific iPS cell lines (n = 7) produced
mature, cystic masses representing all three embryonic germ
layers (Figure 6).The technique of factor-based reprogramming of somatic
cells generates pluripotent stem cell lines that are effectively im-
mortal in culture and can be differentiated into any of a multitude
of human tissues. By comparison of normal and pathologic tis-
sue formation, and by assessment of the reparative effects of
drug treatment in vitro, cell lines generated from patients offer
an unprecedented opportunity to recapitulate pathologic human
tissue formation in vitro, and a new technology platform for drug
screening. The Harvard Stem Cell Institute has committed re-
sources to establish a Core Facility for the production of dis-
ease-specific iPS cell lines, with the goal of making each of these
lines available to the biomedical research community.
EXPERIMENTAL PROCEDURES
Somatic Cell Culture, Isolation, and Culture of iPS Cells
Fibroblasts from patients with ADA-SCID (ADA, GM01390), Gaucher disease
(GD, GM00852), Duchenne type muscular dystrophy (DMD, GM04981;
DMD2, GM05089), Becker type muscular dystrophy (BMD, GM04569), Downs
syndrome (DS1, AG0539A), Parkinson disease (PD, AG20446), juvenile (type I)
diabetes mellitus (JDM, GM02416), Huntington disease (HD, GM04281; HD2,
GM01187), and Lesch-Nyhan syndrome carrier (LNSc, GM00013) were ob-
tained from Coriell. Fibroblasts from patients with Down syndrome (DS2,
DLL54) and normal fetal skin fibroblasts (Detroit 551) were purchased from
ATCC. Bone marrow mesenchymal cells from SBDS patient (SBDS, DF250)
have been described (Austin et al., 2005). Cells were grown in alpha-MEM con-
taining 10% inactivated fetal serum (IFS), 50 U/ml penicillin, 50 mg/ml strepto-
mycin, and 1 mM L-glutamine. Retroviruses expressing OCT4, SOX2, KLF4,Cell 134, 877–886, September 5, 2008 ª2008 Elsevier Inc. 883
Figure 5. Differentiation of Disease-Spe-
cific iPS Cell Lines Reveals Lineage-
Specific Gene Expression and Mature Cell
Formation
(A) At top (from left to right) are eight iPS cell lines in
their undifferentiated (U) or differentiated (D) state.
The lines are adenosine deaminase deficiency-
associated severe combined immunodeficiency
(ADA), juvenile-onset type 1 diabetes mellitus
(JDM), Down syndrome 1 (DS1), Gaucher disease
type III (GD), Huntington disease (HD), Duchenne
muscular dystrophy (DMD), Down syndrome 2
(DS2), and normal control Detroit 551 (551) cells.
Differentiation (D) of these patient-specific iPS
cells as embryoid bodies (EB) followed by RT-
PCR analysis shows upregulated expression of
lineage markers from the three embryonic germ
layers relative to their undifferentiated controls
(U), including: GATA4 and AFP (endoderm),
RUNX1 and Brachyury (mesoderm), and NESTIN
and NCAM (ectoderm). b-ACTIN serves as a
positive amplification control for each.
(B) Differentiation of ADA-iPS2, a representative
patient-specific iPS cell line, as embryoid bodies
(EB) is highly reminiscent of that using hES cells
where tight clusters of differentiating cells are
well-formed by day 7 and will cavitate, becoming cystic, by day 10. Hematopoietic differentiation of patient-specific iPS cells yields various blood cell types
in semisolid methylcellulose colony-forming assays including burst-forming unit-erythroid (BFU-E), which are derivative of red blood cell progenitor cells.and MYC were pseudotyped in VSVg and used to infect 1 3 105 cells in one
well of a six-well dish. iPS cells were isolated as described previously (Park
et al., 2008b). iPS cells from LNSc fibroblasts were isolated using an inducible
lentiviral system as previously described (Stadtfeld et al., 2008). cDNAs en-
coding humanOCT4,SOX2, cMYC,KLF4, andNANOGwere cloned into doxy-
cycline-inducible vectors and were coinfected with a lentivirus harboring a con-
stitutively expressed reverse tetracycline transactivator (rtTA). Infected
fibroblasts were split to feeders under hES culture conditions. Doxycycline
was added to the culture for 30 days and then withdrawn. Colonies that ap-
peared were picked and expanded into lines in the absence of doxycycline.
iPS cell colonies were maintained in hES medium (80% DMEM/F12, 20%
KO Serum Replacement,10 ng/ml bFGF, 1 mM L-glutamine, 100 mM nones-
sential amino acids, 100 mM 2-mercaptoethanol, 50 U/ml penicillin, and
50 mg/ml streptomycin).
Characterization of Genetic Defects in iPS Cells
Genomic DNA was isolated from cells using DNeasy kit (QIAGEN). PCR reac-
tions were performed using 50 ng of genomic DNA with primers corresponding
to the mutated regions of genes responsible for each condition (ADA-SCID,
GD, SBDS [Calado et al., 2007], and HD). Primer sequences are provided in
Table S1. PCR products were resolved via agarose gels, purified and se-
quenced, or cloned into the TOPO vector (Invitrogen) for sequencing. The
number of CAG repeats in the HD gene was determined by amplifying the 50
end of the huntingtin gene by PCR and sequencing. The deletion of exons
within the dystrophin gene in DMD-iPS cells and BMD-iPS cells was deter-
mined by PCR using Chamberlain or Beggs’ multiplex primer sets (Beggs
et al., 1990; Chamberlain et al., 1988).
Karyotype Analysis
Chromosomal studies including karyotype of trisomy 21 in DS1-iPS and DS2-
iPS10 cells were performed at the Cytogenetics Core of the Dana-Farber/Har-
vard Cancer Center or Cell Line Genetics using standard protocols for high-
resolution G-banding.
Fingerprinting Analysis
Fifty nanograms of genomic DNA was used to amplify across discrete genomic
intervals containing highly variable numbers of tandem repeats (VNTR). PCR884 Cell 134, 877–886, September 5, 2008 ª2008 Elsevier Inc.products were resolved in 3% agarose gels to examine the differential ampli-
con mobility for each primer set: D10S1214, repeat (GGAA)n, average hetero-
zygosity 0.97; D17S1290, repeat (GATA)n, average heterozygosity 0.84;
D7S796, repeat (GATA)n, average heterozygosity 0.95; and D21S2055, repeat
(GATA)n, average heterozygosity 0.88 (Invitrogen).
Immunohistochemistry and AP Staining of iPS Cells
iPS cells grown on feeder cells were fixed in 4% paraformaldehyde for 20 min,
permeabilized with 0.2% Triton X-100 for 30 min, and blocked in 3% BSA in
PBS for 2 hr. Cells were incubated with primary antibody overnight at 4C,
washed, and incubated with Alexa Fluor (Invitrogen) secondary antibody for
3 hr. SSEA-3, SSEA-4, TRA 1–60, and TRA 1–81 antibodies were obtained
from Millipore. OCT3/4 and NANOG antibodies were obtained from Abcam. Al-
kaline phosphatase staining was done per the manufacturer’s recommenda-
tions (Millipore).
Analysis of Gene Expression
Total RNA was isolated from iPS cells using an RNeasy kit (QIAGEN) according
to the manufacturer’s protocol. 0.5 mg of RNA was subjected to the RT reaction
using Superscript II (Invitrogen). Quantitative PCR was performed with Brilliant
SYBR Green Master MiX in Stratagene MX3000P machine using previously
described primers (Park et al., 2008b). Semiquantitative PCR was performed
to look at the expression of total, endogenous, and recombinant pluripotency
genes, as well as genes representing the three embryonic germ layers, using
primers described previously and in Table S1.
Differentiation of iPS Cells
iPS cells were washed with DMEM/F12, treated with collagenase for 10 min,
and collected by scraping. Colonies were washed once with DMEM/F12 and
gently resuspended in EB differentiation medium. EBs were differentiated
with low-speed shaking and the medium was changed every 3 days. After 2
weeks of differentiation, EBs were dissociated and plated in MethoCult
(Stem Cell Technologies).
Teratoma Formation from iPS Cells
iPS cells were washed with DMEM/F12, treated with collagenase for 10 min
at room temperature, scraped using glass pipette, and collected by
centrifugation. Cells were washed once with DMEM/F12 and mixed with Ma-
trigel (BD Biosciences) and collagen (Sigma). 2 3 106 cells were intramuscu-
larly injected into immune-deficient Rag2/gC/ mice. After 6 weeks of in-
jection, teratomas were dissected, rinsed once with PBS, and fixed in 10%
formalin. Embedding in paraffin, sectioning of tissue, and hematoxylin/eosin
staining were performed by the Rodent Histopathology service of the Dana-
Farber Cancer Institute.
Figure 6. Disease-Specific iPS Cell Lines Form Teratomas in Immu-
nodeficient Mice
Shown here are the representative series of hematoxylin-eosin (H&E) stained
sections from a formalin-fixed teratoma produced from ADA-iPS2, BMD-
iPS1, DS1-iPS4, HD-iPS1, PD-iPS1, SBDS-iPS3, and JDM-iPS1 cell lines.
They formed mature, cystic teratomas with tissues representing all three em-
bryonic germ layers including respiratory epithelium (endoderm), bone and
cartilage (mesoderm), and pigmented retinal epithelium and immature neural
tissue (ectoderm).SUPPLEMENTAL DATA
Supplemental Data include two figures and one table and can be found with
this article online at http://www.cell.com/cgi/content/full/134/5/877/DC1/.
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